GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Granisetron extended-release injection (SUSTOL)

Granisetron ER (Sustol)

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
SUSTOL: depot formulation matters despite IV granisetron PK

SUSTOL has a longer minimum interval in moderate impairment and avoidance in severe impairment. The separate IV KYTRIL single-dose clearance observation cannot be applied to the polymer depot.

Before applying: Check route and release mechanism; read the local IV record only as a related, noninterchangeable product.

Also check: SUSTOL: depot formulation matters despite IV granisetron PK

Rxlist source

GlobalRPh RX List - Granisetron ER (Sustol)

Product / population
SUSTOL 10 mg subcutaneous extended-release product for chemotherapy-associated nausea/vomiting; not IV KYTRIL.
Renal measure
Creatinine clearance (mL/min).

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Dose and route separately confirmed in turn948264view8.

Renal dosing, restrictions and evidence limits

The usual product dose is 10 mg subcutaneously on day 1 before the specified chemotherapy, with the accompanying antiemetic regimen. At CrCl 30-59, do not administer more often than every 14 days. Avoid SUSTOL below CrCl 30. The polymer vehicle's elimination in renal impairment is uncharacterized; renal restrictions cannot be dismissed because granisetron itself is mainly metabolized hepatically. Do not substitute IV granisetron pharmacokinetic findings for this long-acting formulation's instructions.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/sustol-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

GlobalRPh RX List

GlobalRPh RX List - Granisetron ER (Sustol)

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

SUSTOL 10 mg subcutaneous extended-release product for chemotherapy-associated nausea/vomiting; not IV KYTRIL.

Renal method: Creatinine clearance (mL/min).
Retrieved: 2026-09-07

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

formulation distinction

SUSTOL: depot formulation matters despite IV granisetron PK

SUSTOL has a longer minimum interval in moderate impairment and avoidance in severe impairment. The separate IV KYTRIL single-dose clearance observation cannot be applied to the polymer depot.

How to use this: Check route and release mechanism; read the local IV record only as a related, noninterchangeable product.

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://globalrph.com/rx-list/sustol-drug/

Exact product and population

SUSTOL 10 mg subcutaneous extended-release product for chemotherapy-associated nausea/vomiting; not IV KYTRIL.

RDM39-SCOPE-granisetron-sustol-sc · Source section: Selected source product scopeRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - Granisetron ER (Sustol)

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · SUSTOL 10 mg subcutaneous extended-release product for chemotherapy-associated nausea/vomiting; not IV KYTRIL.

Renal method: Creatinine clearance (mL/min).
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The usual product dose is 10 mg subcutaneously on day 1 before the specified chemotherapy, with the accompanying antiemetic regimen. At CrCl 30-59, do not administer more often than every 14 days. Avoid SUSTOL below CrCl 30. The polymer vehicle's elimination in renal impairment is uncharacterized; renal restrictions cannot be dismissed because granisetron itself is mainly metabolized hepatically. Do not substitute IV granisetron pharmacokinetic findings for this long-acting formulation's instructions.

RDM39-rxlist-granisetron-sustol-sc-fc15ac27e0-C1 · Source locator: Selected renal dosing, use in renal impairment, warnings and clinical pharmacology subsections; see named sections in summary.

Source-specific limits

Dose and route separately confirmed in turn948264view8.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/sustol-drug/
Retrieved
2026-09-07
Renal-function method
Creatinine clearance (mL/min).
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
88455efeb30692419730213463e9d35a717aa59bfbfe0df8bf2bc1de9ed8e31d

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/rx-list/sustol-drug/
Source retrieval
2026-09-07. This is not the source publication or label revision date.
Original source type
rxlist summary
Local text SHA-256
91f012cebeb4fec30d090e0289a1289fa122fff1edf832e9c74f16ae105fce47
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report